Search

A 76-year-old man with severe obstructive sleep apnea (OSA) exhibited lack of efficacy during treatment with cyclophosphamide and rituximab for anti-IgLON 5 disease. The man had a complex medical history including various conditions and medications. Despite receiving the treatment, he developed acute respiratory failure and laryngospasm. He underwent tracheotomy and later experienced nocturnal central hypoventilation, for which he received nocturnal ventilation. [Extracted from the article]

A 42-year-old man with granulomatosis with polyangiitis (GPA) exhibited a lack of efficacy during treatment with cyclophosphamide. He initially presented with bilateral diffuse anterior scleritis and was treated with adalimumab, ciclosporins, and tacrolimus, which reduced his symptoms. However, he experienced worsening symptoms in his left eye, including vitreous opacity and retinal detachment. After receiving prednisolone and rituximab, his symptoms improved, and subsequent imaging showed resolution of the orbital granuloma and retinal detachment. The patient continued maintenance therapy with rituximab and experienced no recurrence of symptoms. [Extracted from the article]

In a case report, two patients with C3 glomerulopathy (C3G) were described. The first patient, a man in his 30s, initially responded to treatment with mycophenolate-mofetil, but later relapsed and showed no response to rituximab and cyclophosphamide therapies. He underwent kidney transplantation and experienced complications, but eventually stabilized with off-label treatment using iptacopan. The second patient, a woman in her 40s, also relapsed after initial improvement and did not respond to eculizumab and rituximab. She underwent kidney transplantation and achieved resolution of C3G with iptacopan treatment. Both patients received vaccinations for various infections. [Extracted from the article]

A 42-year-old man with granulomatosis with polyangiitis (GPA) exhibited a lack of efficacy during treatment with cyclophosphamide. He initially presented with bilateral diffuse anterior scleritis and was treated with adalimumab, ciclosporins, and tacrolimus, which reduced his symptoms. However, he experienced worsening symptoms in his left eye, including vitreous opacity and retinal detachment. After receiving prednisolone and rituximab, his symptoms improved, and follow-up examinations showed resolution of the orbital granuloma and retinal detachment. The patient continued to visit the outpatient clinic with no recurrence of symptoms. [Extracted from the article]

In a case report, two patients with C3 glomerulopathy (C3G) were described. The first patient, a man in his 30s, initially responded to treatment with mycophenolate-mofetil, but later relapsed and showed no response to rituximab and cyclophosphamide therapies. He underwent kidney transplantation and experienced complications, but eventually stabilized with off-label treatment using iptacopan. The second patient, a woman in her 40s, also relapsed after initial improvement and did not respond to eculizumab and rituximab. She underwent kidney transplantation and achieved resolution of C3G with iptacopan treatment. Both patients received vaccinations for various infections. [Extracted from the article]

A 71-year-old woman with a history of various health conditions was treated for granulomatosis with polyangiitis using cyclophosphamide, rituximab, and steroids. However, she experienced a lack of efficacy during the treatment and developed symptoms such as foamy urine, asthenia, fever, cough, and respiratory distress. She required continuous positive airway pressure and was admitted to the intensive care unit. Despite treatment, she experienced complications and was readmitted to the intensive care unit. Eventually, her renal function improved and her clinical condition improved. [Extracted from the article]

An elderly woman experienced lack of efficacy and developed myelosuppression and thrombocytopenia during treatment for type 1 cryoglobulinaemia. She had been receiving various medications, including prednisone, methotrexate, cyclophosphamide, adalimumab, and rituximab. She also had a concurrent bacterial superinfection and was diagnosed with cryoglobulinaemic glomerulonephropathy. After being admitted to the hospital, she received bortezomib, methylprednisolone, and plasma exchange, which led to pancytopenia and pseudomonal septicaemia. The myelosuppression was attributed to cyclophosphamide, and the thrombocytopenia was attributed to cyclophosphamide and bortezomib. Her condition gradually improved with treatment adjustments and she was eventually discharged. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 48-year-old woman developed primary cutaneous marginal zone B-cell lymphomas (PCMZLs) during treatment with cyclophosphamide, doxorubicin and paclitaxel for left breast cancer. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 52-year-old woman exhibited treatment failure during treatment with rituximab and unspecified steroids and developed acute promyelocytic leukaemia (APL) during treatment with cyclophosphamide for granulomatosis with polyangiitis [GPA; not all dosages stated; routes and duration of treatment to reaction onset not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 69-year-old man developed Klebsiella infection, Pseudomonas pneumonia and infections during treatment with methylprednisolone, rituximab or cyclophosphamide for ANCA-associated crescentic glomerulonephritis [duration of treatments to reactions onsets, routes and outcomes for ADRs not stated; not all dosages stated]. [Extracted from the article]

In a recent analysis, two women, aged 53 and 48, were found to have experienced a lack of effectiveness in their treatment with cyclophosphamide for monoclonal gammopathy of renal significance and cyclophosphamide, unspecified steroids, and rituximab for profound nephrotic syndrome. Furthermore, one of the women experienced anaphylaxis during treatment with rituximab. The specific dosages, duration of treatment, and outcomes of these adverse reactions were not provided in the analysis. [Extracted from the article]

A 26-year-old woman developed neutropenic sepsis while undergoing treatment for B cell lymphoma and nasopharyngeal carcinoma. She received chemotherapy with cyclophosphamide, doxorubicin, rituximab, and vincristine, and had previously undergone left laparoscopic oophorectomy. The onset and outcome of the reaction are not specified in the article. [Extracted from the article]

A 50-year-old woman with mantle cell lymphoma experienced a lack of efficacy during treatment with cyclophosphamide, vincristine, doxorubicin, dexamethasone, rituximab, and acalabrutinib. Initially, she developed a pink plaque on her lower back, which was diagnosed as mantle cell lymphoma. Despite receiving chemotherapy, her lesions increased in size and number, and she developed B symptoms. Biopsies revealed myeloid sarcoma and recurrent mantle cell lymphoma, indicating a lack of efficacy with the prescribed drugs. The patient is now being considered for alternative therapies, including anti-CD19 CART-cell therapy and allogeneic stem cell transplant. [Extracted from the article]

A retrospective study involving 65 patients who underwent allogeneic blood marrow transplantation (alloBMT) for peripheral T Cell lymphoma found that one patient developed therapy-related myeloid neoplasm during treatment with fludarabine, cyclophosphamide, and mycophenolate-mofetil. The patient received non-myeloablative conditioning with IV fludarabine and cyclophosphamide, as well as total body irradiation. After the alloBMT, the patient received IV cyclophosphamide and mycophenolate mofetil for graft-versus-host disease prophylaxis. The duration of treatment and outcome of the patient's reaction were not stated. [Extracted from the article]

A case report published in Reactions Weekly describes a 59-year-old woman who experienced a lack of efficacy while being treated with prednisolone and rituximab for myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis (AAV). The woman initially presented with a headache and was diagnosed with MPO-AAV. She was treated with methylprednisolone, prednisone, and cyclophosphamide, and her symptoms improved. However, she experienced a recurrence of AAV and was treated with prednisolone and rituximab, but her symptoms did not improve. Her treatment was adjusted, and her symptoms gradually improved. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 52-year-old woman developed serum sickness reaction, paraproteinaemia of IgM kappa type, acute kidney injury (AKI) and pupuric rash with skin ulcers during treatment with rituximab. She had a relapse again in July 2021, and she was diagnosed with monoclonal paraproteinaemia of IgM kappa type, worsening proteinuria, 29% cryoglobulin levels, AKI (acute kidney injury) and purpuric rash with skin ulcers. Initially, she showed an improvement, and her cryoglobulin level was dropped to 3%, but it relapsed (lack of efficacy) again when prednisone dose was reduced, while receiving cyclophosphamide [Cytoxan]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective cohort study of 270 children conducted between 2006 and 2018, two children [ I sexes and exact ages not stated i ] were described, who developed neutropenia during treatment with cyclophosphamide or rituximab for frequently relapsing/steroid-dependent nephrotic syndrome [FR/SDNS; I not all dosages and routes stated i ]. Subsequently, the children developed neutropenia secondary to rituximab (1 patient) and neutropenia secondary to cyclophosphamide and rituximab (1 patient). [Extracted from the article]

He was then treated with oral cyclophosphamide 50mg twice daily, but he was unable to tolerate it due to the side-effect of fatigue [ I duration of treatment to reaction onset and outcome not stated i ]. At the age of 45 years, he was hospitalised for further evaluation and treatment, which led to the diagnosis of metastatic MSFT complicated with paraneoplastic Doege-Potter syndrome. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 45-year-old man developed fatigue during treatment with cyclophosphamide and exhibited lack of efficacy during treatment with pazopanib for metastatic malignant solitary fibrous tumour [MSFT; I not all routes stated i ]. [Extracted from the article]

Also, he developed chemotherapy-related grade-III agranulocytosis [ I durations of treatments to reactions onsets not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 67-year-old man developed agranulocytosis while receiving chemotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukaemia (CLL). Prior to chemotherapy, he was also started on unspecified anti HBV-drugs (Hepatitis-B core antibody and hepatitis-B surface antibody were positive). [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 15-year-old girl exhibited lack of efficacy during treatment with cyclophosphamide, methylprednisolone and mycophenolate mofetil for nephrotic syndrome [ I not all routes and dosages stated i ]. Thereafter, IV cyclophosphamide was added to the therapy, however, she was still unresponsive the therapy in week 6. [Extracted from the article]

Out of these 2 patients, one patient died after 11 months whereas, the other patient died after 3 years of receiving PT [ I immediate cause of death not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective study involving 29 patients treated between 2011 and 2021, et al. patients [ I ages and sexes not stated i ] were described, who exhibited lack of efficacy during treatment with cyclophosphamide, prednisone and rituximab for aggressive mediastinal non-Hodgkin lymphoma (AMNHL) [ I dosages and routes not stated i ]. [Extracted from the article]

However, the patient's localised parotid lymphoma, clinical, histological and molecular signs of lymphoma persisted despite receiving treatment. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a study, comprising 14 patients, a patient [ I age and sex not stated i ] was described, who exhibited lack of efficacy during treatment with cyclophosphamide, rituximab and chlorambucil for MALT-lymphomas (MALT-L) in primary Sjogren's syndrome (pSS) [ I routes and dosages not stated i ]. The patient, who was diagnosed with MALT-L in pSS treated initially with rituximab and cyclophosphamide and later with rituximab and chlorambucil. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 52-year-old woman exhibited lack of efficacy during treatment with cyclophosphamide, methylprednisolone and rituximab for GAD65 encephalitis [ I not all durations of treatment, routes and dosages stated i ]. Three cycles of cyclophosphamide were continued with methylprednisolone in maintenance dose. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 75-year-old man developed rash during treatment with cyclophosphamide, dexamethasone and rituximab for ocular adnexal Waldenstrom macroglobulinemia (WM). As only symptomatic orbital involvement was noted, he started receiving treatment with IV infusion rituximab 375 mg/m SP 2 sp (on day 1), oral cyclophosphamide 100 mg/m SP 2 sp (days 1-4) and oral dexamethasone 40mg weekly. However, he developed treatment-related grade-III rash requiring treatment cessation [ I duration of treatment to reaction onset and outcome not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A woman [ I age at the time of reaction onset not stated i ] exhibited lack of efficacy during treatment with methotrexate, rituximab and cyclophosphamide for adult-onset asthma and periocular xanthogranuloma (AAPOX) [ I dosages and routes not stated i ]. Orbitotomy with excision involved an upper eyelid crease incision was performed. [Extracted from the article]